These findings indicate that activation of the PI3K/AKT pathway is likely a causal genetic event in the luminal subtype of breast cancer; thereby, inhibition of this pathway represents a top priority for therapeutic intervention. The gene discussed is AKT1; the disease is breast carcinoma.